A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas/paragangliomas
Author:
Funder
National High Level Hospital Clinical Research Funding
CAMS Innovation Fund for Medical Sciences (CIFMS) of China
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s40618-024-02398-z.pdf
Reference14 articles.
1. Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab 99(6):1915–1942
2. Granberg D, Juhlin CC, Falhammar H (2021) Metastatic pheochromocytomas and abdominal paragangliomas [J]. J Clin Endocrinol Metab 106(5):e1937–e1952
3. Mete O, Asa SL, Gill AJ et al (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas [J]. Endocr Pathol 33(1):90–114
4. Hescot S, Leboulleux S, Amar L et al (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma [J]. J Clin Endocrinol Metab 98(10):4006–4012
5. Zhou Y, Cui Y, Zhang D et al (2022) Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic pheochromocytomas/paragangliomas: a systematic review and meta-analysis [J]. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgac657
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3